Skip to main content
participate

Participate in a Trial

Start your journey

NCT06015282 | PHASE 3 | INTERVENTIONAL

Influenza, Human

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

96 Sites
7741 Participants
ACTIVE NOT RECRUITING
50 Years to 45 Years
NCT03569891 | PHASE 3 | INTERVENTIONAL

Hemophilia B

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

33 Sites
67 Participants
ACTIVE NOT RECRUITING
18 Years to 75 Years
NCT06087640 | PHASE 3 | INTERVENTIONAL

Influenza, Human

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

90 Sites
35800 Participants
ACTIVE NOT RECRUITING
65 Years to 65 Years
NCT04167514 | PHASE 3 | INTERVENTIONAL

Graft Versus Host Disease (GVHD)

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

25 Sites
136 Participants
ACTIVE NOT RECRUITING
12 Years to 8 Years
NCT04864795 | PHASE 3 | OBSERVATIONAL

Heart Failure

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

116 Sites
2636 Participants
ACTIVE NOT RECRUITING
18 Years to 64 Years
NCT04675541 | PHASE 2 | OBSERVATIONAL

Haemophilia A

Register of Patients With haEmophilia A tReated With Afstyla®

17 Sites
62 Participants
ACTIVE NOT RECRUITING
18 Years to 50 Years
NCT04044690 | PHASE 3 | INTERVENTIONAL

Dermatomyositis

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

76 Sites
126 Participants
ACTIVE NOT RECRUITING
18 Years to 8 Years
NCT05874713 | PHASE 2 | INTERVENTIONAL

Influenza, Human

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

9 Sites
480 Participants
ACTIVE NOT RECRUITING
18 Years to 60 Years
NCT04739059 | PHASE 3 | INTERVENTIONAL

Hereditary Angioedema

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

44 Sites
171 Participants
ACTIVE NOT RECRUITING
12 Years to 59 Months
NCT05360706 | PHASE 3 | OBSERVATIONAL

Hemophilia B

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

6 Sites
9 Participants
ACTIVE NOT RECRUITING
18 Years to 17 Years
NCT05460234 | PHASE 3 | OBSERVATIONAL

Chronic Kidney Disease

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients

16 Sites
110 Participants
ACTIVE NOT RECRUITING
18 Years to 11 Years
NCT04262284 | PHASE 2 | OBSERVATIONAL

Alpha-1 Antitrypsin Deficiency

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

11 Sites
60 Participants
ACTIVE NOT RECRUITING
18 Years to 65 Years
NCT05875961 | PHASE 1 | INTERVENTIONAL

Influenza, Human

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

7 Sites
600 Participants
ACTIVE NOT RECRUITING
18 Years to 47 Months
NCT06028347 | PHASE 1 | INTERVENTIONAL

Influenza, Human

Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults

2 Sites
96 Participants
ACTIVE NOT RECRUITING
18 Years to 85 Years
NCT03177005 | PHASE 4 | EXPANDED_ACCESS

Influenza, Human

Expanded Access for Hereditary Angioedema (HAE)

0 Sites
120 Participants
APPROVED FOR MARKETING
18 Years to 65 Years
NCT02093897 | PHASE 3 | INTERVENTIONAL

Congenital Hemophilia A

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

37 Sites
84 Participants
COMPLETED
18 Years to 11 Years
NCT01130597 | PHASE 2 | INTERVENTIONAL

Heart Failure

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

13 Sites
63 Participants
COMPLETED
18 Years to 11 Years
NCT00542997 | PHASE 3 | INTERVENTIONAL

Common Variable Immunodeficiency

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

19 Sites
51 Participants
COMPLETED
2 Years to 65 Years
NCT05501561 | PHASE 2 | INTERVENTIONAL

Influenza, Human

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

47 Sites
1056 Participants
COMPLETED
50 Years to 65 Years
NCT01199705 | PHASE 3 | INTERVENTIONAL

Primary Immune Deficiency

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

10 Sites
25 Participants
COMPLETED
18 Years to 75 Years
NCT02126761 | PHASE 1 | INTERVENTIONAL

Influenza

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

1 Sites
196 Participants
COMPLETED
65 Years to 75 Years
NCT02470871 | PHASE 1 | INTERVENTIONAL

Congenital Coagulation Factor VII Deficiency

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

2 Sites
9 Participants
COMPLETED
18 Years to 47 Months
NCT04082754 | PHASE 1 | INTERVENTIONAL

Asthma

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

3 Sites
78 Participants
COMPLETED
18 Years to 65 Years
NCT01857297 | PHASE 4 | INTERVENTIONAL

Influenza, Human

A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

1 Sites
120 Participants
COMPLETED
18 Years to 65 Years
NCT01458171 | PHASE 3 | INTERVENTIONAL

Primary Immune Deficiency Disorder

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

9 Sites
23 Participants
COMPLETED
18 Years to 75 Years
NCT02711228 | PHASE 4 | INTERVENTIONAL

Primary Immune Deficiency

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

2 Sites
26 Participants
COMPLETED
5 Years to 64 Years
NCT01324128 | PHASE 3 | INTERVENTIONAL

Chronic Kidney Disease Requiring Chronic Dialysis

A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

15 Sites
1059 Participants
COMPLETED
18 Years to 64 Years
NCT04074928 | PHASE 3 | INTERVENTIONAL

Influenza

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

47 Sites
2414 Participants
COMPLETED
6 Months to 47 Months
NCT01438359 | PHASE 1 | INTERVENTIONAL

Healthy

A Drug-Drug Interaction Study of Furosemide and PA21

1 Sites
42 Participants
COMPLETED
20 Years to 50 Years
NCT04657887 | PHASE 1 | OBSERVATIONAL

Von Willebrand Disease

Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

17 Sites
135 Participants
COMPLETED
20 Years to 50 Years
NCT04643587 | PHASE 1 | INTERVENTIONAL

Noncystic Fibrosis Bronchiectasis (NCFB)

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

3 Sites
64 Participants
COMPLETED
18 Years to 50 Years
NCT02583256 | PHASE 3 | INTERVENTIONAL

Influenza

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

17 Sites
1601 Participants
COMPLETED
12 Months to 7 Years
NCT00322556 | PHASE 3 | INTERVENTIONAL

Agammaglobulinemia

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

10 Sites
55 Participants
COMPLETED
4 Years to 71 Years
NCT01110356 | PHASE 4 | INTERVENTIONAL

Iron Deficiency

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

1 Sites
294 Participants
COMPLETED
18 Years to 71 Years
NCT01912456 | PHASE 3 | INTERVENTIONAL

Hereditary Angioedema Types I and II

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

39 Sites
90 Participants
COMPLETED
12 Years to 71 Years
NCT02107807 | PHASE 3 | INTERVENTIONAL

Influenza, Human

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

17 Sites
539 Participants
COMPLETED
18 Years to 71 Years
NCT01229007 | PHASE 3 | INTERVENTIONAL

Hemophilia A

Study of Biostate® in Children With Hemophilia A

8 Sites
35 Participants
COMPLETED
18 Years to 12 Years
NCT04409509 | PHASE 2 | INTERVENTIONAL

Coronavirus Disease 2019 (COVID-19)

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

14 Sites
124 Participants
COMPLETED
18 Years to 12 Years
NCT00670007 | PHASE 4 | INTERVENTIONAL

Emphysema

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

21 Sites
140 Participants
COMPLETED
18 Years to 12 Years
NCT03438487 | PHASE 4 | OBSERVATIONAL

Influenza, Human

Flucelvax (TIVc or QIVc) Pregnancy Registry

1 Sites
692 Participants
COMPLETED
18 Years to 12 Years
NCT01477411 | PHASE 1 | INTERVENTIONAL

Drug Interaction Potentiation

A Drug-Drug Interaction Study of Digoxin and PA21

1 Sites
42 Participants
COMPLETED
20 Years to 50 Years
NCT01467947 | PHASE 4 | INTERVENTIONAL

Hereditary Angioedema Types I and II

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

4 Sites
46 Participants
COMPLETED
12 Years to 85 Years
NCT03033745 | PHASE 4 | INTERVENTIONAL

Primary Immunodeficiency

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

12 Sites
49 Participants
COMPLETED
2 Years to 85 Years
NCT00168077 | PHASE 3 | INTERVENTIONAL

Acquired Coagulation Factor Deficiency

Prothrombin Complex Concentrate for Anticoagulant Reversal

15 Sites
40 Participants
COMPLETED
18 Years to 85 Years
NCT01373151 | PHASE 2 | INTERVENTIONAL

Rheumatoid Arthritis

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

100 Sites
418 Participants
COMPLETED
18 Years to 85 Years
NCT02316353 | PHASE 3 | INTERVENTIONAL

Hereditary Angioedema Types I and II

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

32 Sites
126 Participants
COMPLETED
6 Years to 85 Years
NCT02937454 | PHASE 4 | INTERVENTIONAL

Iron Deficiency

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

16 Sites
1132 Participants
COMPLETED
18 Years to 85 Years
NCT04580654 | PHASE 1 | INTERVENTIONAL

Healthy Volunteers

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

1 Sites
38 Participants
COMPLETED
18 Years to 55 Years
NCT03047954 | PHASE 3 | INTERVENTIONAL

Atopic Dermatitis

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

0 Sites
179 Participants
COMPLETED
6 Months to 7 Years
NCT00994318 | PHASE 3 | INTERVENTIONAL

Iron Deficiency Anaemia

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

19 Sites
626 Participants
COMPLETED
18 Years to 59 Years
NCT00701662 | PHASE 2 | INTERVENTIONAL

Multifocal Motor Neuropathy (MMN)

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

3 Sites
8 Participants
COMPLETED
18 Years to 59 Years
NCT04669691 | PHASE 2 | INTERVENTIONAL

Influenza, Human

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

7 Sites
420 Participants
COMPLETED
6 Months to 8 Years
NCT02694744 | PHASE 4 | INTERVENTIONAL

Hyperkalemia

Patiromer With or Without Food for the Treatment of Hyperkalemia

29 Sites
114 Participants
COMPLETED
18 Years to 8 Years
NCT02108262 | PHASE 2 | INTERVENTIONAL

Acute Myocardial Infarction

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

189 Sites
1267 Participants
COMPLETED
18 Years to 8 Years
NCT02396342 | PHASE 1 | INTERVENTIONAL

Hemophilia B

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

7 Sites
10 Participants
COMPLETED
18 Years to 64 Years
NCT00701142 | PHASE 2 | INTERVENTIONAL

Aortic Aneurysm

Haemocomplettan® P During Aortic Replacement

1 Sites
80 Participants
COMPLETED
18 Years to 64 Years
NCT01390649 | PHASE 4 | INTERVENTIONAL

Immune Thrombocytopenic Purpura

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

17 Sites
57 Participants
COMPLETED
18 Years to 65 Years
NCT00885742 | PHASE 3 | INTERVENTIONAL

Factor XIII Deficiency

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

23 Sites
41 Participants
COMPLETED
18 Years to 65 Years
NCT00700193 | PHASE 3 | INTERVENTIONAL

Influenza

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

1 Sites
298 Participants
COMPLETED
6 Months to 8 Years
NCT02255409 | PHASE 3 | INTERVENTIONAL

Influenza

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05

28 Sites
607 Participants
COMPLETED
12 Months to 84 Months
NCT05306275 | PHASE 1 | INTERVENTIONAL

Healthy Participants

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

1 Sites
132 Participants
COMPLETED
18 Years to 55 Years
NCT03712228 | PHASE 2 | INTERVENTIONAL

Hereditary Angioedema

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

16 Sites
44 Participants
COMPLETED
18 Years to 65 Years
NCT01863433 | PHASE 4 | INTERVENTIONAL

Influenza, Human

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

1 Sites
120 Participants
COMPLETED
18 Years to 59 Years
NCT00701545 | PHASE 1 | OBSERVATIONAL

Von Willebrand Disease

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

1 Sites
21 Participants
COMPLETED
18 Years to 55 Years
NCT01371747 | PHASE 2 | INTERVENTIONAL

Chronic Kidney Disease

Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

43 Sites
324 Participants
COMPLETED
30 Years to 80 Years
NCT00376402 | PHASE 2 | INTERVENTIONAL

Influenza

Study of a Pandemic Influenza Vaccine in Elderly Participants

2 Sites
200 Participants
COMPLETED
65 Years to 65 Years
NCT04576702 | PHASE 2 | INTERVENTIONAL

Influenza

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

21 Sites
471 Participants
COMPLETED
50 Years to 65 Years
NCT02545543 | PHASE 3 | INTERVENTIONAL

Influenza, Human

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

32 Sites
2278 Participants
COMPLETED
5 Years to 17 Years
NCT01760343 | PHASE 1 | INTERVENTIONAL

Hereditary Angioedema Types I and II

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

1 Sites
16 Participants
COMPLETED
18 Years to 45 Years
NCT01347190 | PHASE 1 | INTERVENTIONAL

Cystic Fibrosis

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

11 Sites
25 Participants
COMPLETED
18 Years to 65 Years
NCT00562484 | PHASE 4 | INTERVENTIONAL

Influenza

A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

24 Sites
7500 Participants
COMPLETED
18 Years to 64 Years
NCT00883090 | PHASE 2 | INTERVENTIONAL

Factor XIII Deficiency

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

6 Sites
15 Participants
COMPLETED
18 Years to 64 Years
NCT00261833 | PHASE 4 | INTERVENTIONAL

Alpha1-proteinase Inhibitor Deficiency

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

28 Sites
180 Participants
COMPLETED
18 Years to 65 Years
NCT03591406 | PHASE 3 | INTERVENTIONAL

Iron Deficiency Anemia

To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

1 Sites
371 Participants
COMPLETED
18 Years to 65 Years
NCT01101399 | PHASE 3 | INTERVENTIONAL

Iron-Deficiency Anemia

Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy

2 Sites
19 Participants
COMPLETED
18 Years to 65 Years
NCT01452906 | PHASE 1 | INTERVENTIONAL

Healthy

A Drug-Drug Interaction Study of Omeprazole and PA21

1 Sites
45 Participants
COMPLETED
20 Years to 50 Years
NCT01053715 | PHASE 1 | OBSERVATIONAL

Hemophilia A

Quality of Life Study of Helixate NexGen

31 Sites
78 Participants
COMPLETED
14 Years to 35 Years
NCT01324752 | PHASE 1 | INTERVENTIONAL

Drug Interaction Potentiation

A Drug-Drug Interaction Study of Losartan and PA21

1 Sites
36 Participants
COMPLETED
20 Years to 50 Years
NCT05077436 | PHASE 1 | INTERVENTIONAL

Healthy

Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

1 Sites
28 Participants
COMPLETED
18 Years to 60 Years
NCT05452317 | PHASE 3 | OBSERVATIONAL

Antibody-mediated Rejection in Kidney Transplant

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

3 Sites
52 Participants
COMPLETED
18 Years to 11 Years
NCT01591837 | PHASE 4 | INTERVENTIONAL

Influenza, Human

A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

1 Sites
120 Participants
COMPLETED
18 Years to 45 Years
NCT03165617 | PHASE 3 | INTERVENTIONAL

Influenza, Human

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

40 Sites
4514 Participants
COMPLETED
2 Years to 17 Years
NCT05653713 | PHASE 1 | INTERVENTIONAL

Healthy Volunteers

Effects of CSL324 in the Lung After Segmental Challenge

1 Sites
40 Participants
COMPLETED
18 Years to 65 Years
NCT04656418 | PHASE 3 | INTERVENTIONAL

Hereditary Angioedema

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

28 Sites
64 Participants
COMPLETED
12 Years to 65 Years
NCT02587221 | PHASE 3 | INTERVENTIONAL

Influenza

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

89 Sites
6790 Participants
COMPLETED
65 Years to 65 Years
NCT02742103 | PHASE 2 | INTERVENTIONAL

Acute Myocardial Infarction

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

31 Sites
83 Participants
COMPLETED
18 Years to 65 Years
NCT00168103 | PHASE 2 | INTERVENTIONAL

Hereditary Angioedema

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

36 Sites
126 Participants
COMPLETED
6 Years to 65 Years
NCT00168090 | PHASE 4 | INTERVENTIONAL

Von Willebrand Disease

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

1 Sites
30 Participants
COMPLETED
6 Years to 65 Years
NCT05130970 | PHASE 2 | INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

47 Sites
81 Participants
COMPLETED
40 Years to 55 Years
NCT00866970 | PHASE 2 | INTERVENTIONAL

NSCLC

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

43 Sites
124 Participants
COMPLETED
18 Years to 59 Months
NCT04817670 | PHASE 2 | INTERVENTIONAL

Sickle Cell Disease

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

22 Sites
25 Participants
COMPLETED
18 Years to 60 Years
NCT00735475 | PHASE 4 | INTERVENTIONAL

Influenza

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

13 Sites
1268 Participants
COMPLETED
65 Years to 60 Years
NCT02914275 | PHASE 3 | INTERVENTIONAL

Influenza, Human

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

39 Sites
2250 Participants
COMPLETED
6 Months to 59 Months
NCT00867516 | PHASE 2 | INTERVENTIONAL

Arthritis, Rheumatoid

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

26 Sites
127 Participants
COMPLETED
18 Years to 80 Years
NCT00945906 | PHASE 3 | INTERVENTIONAL

Factor XIII Deficiency

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

25 Sites
61 Participants
COMPLETED
18 Years to 80 Years
NCT02212106 | PHASE 4 | INTERVENTIONAL

Influenza, Human

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

11 Sites
402 Participants
COMPLETED
5 Years to 8 Years
NCT00959049 | PHASE 3 | INTERVENTIONAL

Influenza

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

23 Sites
1474 Participants
COMPLETED
6 Months to 17 Years
NCT02427035 | PHASE 1 | INTERVENTIONAL

Acute Myocardial Infarction

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

4 Sites
32 Participants
COMPLETED
18 Years to 85 Years
NCT00168038 | PHASE 3 | INTERVENTIONAL

Immune Thrombocytopenic Purpura

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

17 Sites
58 Participants
COMPLETED
12 Years to 65 Years
NCT01224808 | PHASE 3 | INTERVENTIONAL

Von Willebrand Disease

Extension Study of Biostate in Subjects With Von Willebrand Disease

6 Sites
20 Participants
COMPLETED
12 Years to 65 Years
NCT00940108 | PHASE 2 | INTERVENTIONAL

Influenza Caused by the Novel Influenza A (H1N1) Virus

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

5 Sites
370 Participants
COMPLETED
6 Months to 8 Years
NCT00370864 | PHASE 2 | INTERVENTIONAL

Influenza

Study of a Pandemic Influenza Vaccine in Children

2 Sites
220 Participants
COMPLETED
6 Months to 8 Years
NCT00812019 | PHASE 1 | INTERVENTIONAL

Influenza

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

2 Sites
753 Participants
COMPLETED
18 Years to 40 Years
NCT00320346 | PHASE 2 | INTERVENTIONAL

Influenza

Phase II Study of Pandemic Influenza Vaccine

3 Sites
400 Participants
COMPLETED
18 Years to 64 Years
NCT04782323 | PHASE 2 | INTERVENTIONAL

Influenza

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

30 Sites
839 Participants
COMPLETED
50 Years to 64 Years
NCT01576523 | PHASE 1 | INTERVENTIONAL

Hereditary Angioedema Types I and II

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

8 Sites
18 Participants
COMPLETED
18 Years to 64 Years
NCT03473223 | PHASE 3 | INTERVENTIONAL

Acute Coronary Syndrome

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

903 Sites
18200 Participants
COMPLETED
18 Years to 64 Years
NCT01453608 | PHASE 4 | INTERVENTIONAL

Iron Deficiency

A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

2 Sites
304 Participants
COMPLETED
18 Years to 75 Years
NCT01053169 | PHASE 4 | OBSERVATIONAL

Coagulation Protein Disorders

Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)

6 Sites
445 Participants
COMPLETED
16 Years to 75 Years
NCT01184846 | PHASE 3 | INTERVENTIONAL

Chronic Inflammatory Demyelinating Polyneuropathy

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

22 Sites
31 Participants
COMPLETED
18 Years to 75 Years
NCT00168012 | PHASE 3 | INTERVENTIONAL

Agammaglobulinemia

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

0 Sites
42 Participants
COMPLETED
3 Years to 70 Years
NCT02172950 | PHASE 3 | INTERVENTIONAL

Hemophilia A

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

64 Sites
246 Participants
COMPLETED
18 Years to 60 Years
NCT01490450 | PHASE 2 | INTERVENTIONAL

Arthritis, Psoriatic

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

49 Sites
165 Participants
COMPLETED
18 Years to 60 Years
NCT00958243 | PHASE 2 | INTERVENTIONAL

Influenza

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

13 Sites
473 Participants
COMPLETED
6 Months to 9 Years
NCT02091908 | PHASE 3 | INTERVENTIONAL

Influenza, Human

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions

6 Sites
540 Participants
COMPLETED
18 Years to 9 Years
NCT00941616 | PHASE 2 | INTERVENTIONAL

Von Willebrand Disease

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

5 Sites
22 Participants
COMPLETED
12 Years to 50 Years
NCT00419341 | PHASE 3 | INTERVENTIONAL

Primary Immune Deficiency

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

13 Sites
49 Participants
COMPLETED
2 Years to 75 Years
NCT01542619 | PHASE 1 | INTERVENTIONAL

Healthy

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

1 Sites
40 Participants
COMPLETED
18 Years to 35 Years
NCT02427217 | PHASE 1 | OBSERVATIONAL

Congenital Fibrinogen Deficiency

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

11 Sites
22 Participants
COMPLETED
18 Years to 35 Years
NCT01461018 | PHASE 3 | INTERVENTIONAL

Primary Immune Deficiency

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

9 Sites
22 Participants
COMPLETED
18 Years to 75 Years
NCT00879541 | PHASE 2 | INTERVENTIONAL

Hemophilia A

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

14 Sites
81 Participants
COMPLETED
12 Years to 75 Years
NCT00751621 | PHASE 3 | INTERVENTIONAL

Primary Immunodeficiency (PID)

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

13 Sites
40 Participants
COMPLETED
2 Years to 65 Years
NCT01464190 | PHASE 3 | INTERVENTIONAL

Chronic Kidney Disease Requiring Chronic Dialysis

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

15 Sites
659 Participants
COMPLETED
18 Years to 65 Years
NCT01034904 | PHASE 3 | OBSERVATIONAL

Hemophilia A

Health Related Quality of Life of Youth and Young Adults With Hemophilia A

2 Sites
48 Participants
COMPLETED
14 Years to 30 Years
NCT04364269 | PHASE 2 | INTERVENTIONAL

Beta-Thalassemia

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia

16 Sites
35 Participants
COMPLETED
12 Years to 65 Years
NCT01475669 | PHASE 3 | INTERVENTIONAL

Surgical Blood Loss

Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery

35 Sites
152 Participants
COMPLETED
18 Years to 65 Years
NCT01213446 | PHASE 3 | INTERVENTIONAL

Von Willebrand Disease

Study of Biostate® in Children With Von Willebrand Disease

7 Sites
17 Participants
COMPLETED
18 Years to 12 Years
NCT02281201 | PHASE 3 | INTERVENTIONAL

Acute Major Bleeding

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

11 Sites
11 Participants
COMPLETED
20 Years to 12 Years
NCT04419467 | PHASE 2 | INTERVENTIONAL

Diabetic Kidney Disease (DKD)

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

37 Sites
114 Participants
COMPLETED
25 Years to 12 Years
NCT02027701 | PHASE 3 | INTERVENTIONAL

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

33 Sites
82 Participants
COMPLETED
18 Years to 12 Years
NCT01477424 | PHASE 1 | INTERVENTIONAL

Drug Interaction Potentiation

A Drug-Drug Interaction Study of Warfarin and PA21

1 Sites
45 Participants
COMPLETED
20 Years to 50 Years
NCT04137224 | PHASE 2 | INTERVENTIONAL

Diffuse Cutaneous Systemic Sclerosis

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

9 Sites
27 Participants
COMPLETED
18 Years to 50 Years
NCT05044195 | PHASE 3 | INTERVENTIONAL

Influenza, Human

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

29 Sites
2044 Participants
COMPLETED
50 Years to 64 Years
NCT00719680 | PHASE 3 | INTERVENTIONAL

Primary Immune Deficiency

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

4 Sites
21 Participants
COMPLETED
2 Years to 75 Years
NCT01810939 | PHASE 3 | INTERVENTIONAL

Chronic Kidney Disease (CKD)

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

58 Sites
243 Participants
COMPLETED
18 Years to 80 Years
NCT00938639 | PHASE 2 | INTERVENTIONAL

Influenza Caused by the Novel Influenza A (H1N1) Virus

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

1 Sites
240 Participants
COMPLETED
18 Years to 64 Years
NCT00868439 | PHASE 2 | INTERVENTIONAL

Hyperkalemia

Evaluation of Patiromer in Heart Failure Patients

33 Sites
120 Participants
COMPLETED
18 Years to 64 Years
NCT02035696 | PHASE 1 | INTERVENTIONAL

Influenza

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

27 Sites
671 Participants
COMPLETED
6 Months to 48 Months
NCT02214225 | PHASE 3 | INTERVENTIONAL

Influenza, Human

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

33 Sites
3484 Participants
COMPLETED
18 Years to 48 Months
NCT01131624 | PHASE 3 | INTERVENTIONAL

Anaemia

Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women

20 Sites
252 Participants
COMPLETED
18 Years to 48 Months
NCT00824460 | PHASE 2 | INTERVENTIONAL

Chronic Kidney Disease

Study of Phosphate Levels in Patients With Chronic Kidney Disease

60 Sites
154 Participants
COMPLETED
18 Years
NCT03932682 | PHASE 3 | INTERVENTIONAL

Influenza, Human

Efficacy Study With QIVc in Pediatric Subjects

74 Sites
5723 Participants
COMPLETED
6 Months to 47 Months
NCT01662531 | PHASE 3 | INTERVENTIONAL

Hemophilia B

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

17 Sites
27 Participants
COMPLETED
6 Months to 11 Years
NCT00136331 | PHASE 1 | INTERVENTIONAL

Influenza

Study of a Pandemic Influenza Vaccine

2 Sites
400 Participants
COMPLETED
18 Years to 45 Years
NCT01545076 | PHASE 3 | INTERVENTIONAL

Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

91 Sites
208 Participants
COMPLETED
18 Years to 45 Years
NCT02839330 | PHASE 3 | INTERVENTIONAL

Avian Influenza

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

26 Sites
3196 Participants
COMPLETED
18 Years to 70 Years
NCT03071263 | PHASE 2 | INTERVENTIONAL

Hyperkalemia

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

40 Sites
295 Participants
COMPLETED
18 Years to 70 Years
NCT00708435 | PHASE 3 | INTERVENTIONAL

Blood Coagulation Disorders

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

69 Sites
216 Participants
COMPLETED
18 Years to 70 Years
NCT03489291 | PHASE 2 | INTERVENTIONAL

Hemophilia B

Dose Confirmation Trial of AAV5-hFIXco-Padua

4 Sites
3 Participants
COMPLETED
18 Years to 75 Years
NCT01063140 | PHASE 2 | OBSERVATIONAL

Rabies

Rabies Immune Plasma Booster Study

10 Sites
491 Participants
COMPLETED
18 Years to 75 Years
NCT00888381 | PHASE 4 | INTERVENTIONAL

Influenza

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

1 Sites
120 Participants
COMPLETED
18 Years to 75 Years
NCT00825162 | PHASE 4 | INTERVENTIONAL

Influenza

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

7 Sites
1992 Participants
COMPLETED
6 Months to 17 Years
NCT03314662 | PHASE 3 | INTERVENTIONAL

Influenza, Human

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

20 Sites
1778 Participants
COMPLETED
65 Years to 17 Years
NCT00803101 | PHASE 3 | INTERVENTIONAL

Reversal of Coagulopathy

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

30 Sites
176 Participants
COMPLETED
18 Years to 17 Years
NCT00810004 | PHASE 3 | INTERVENTIONAL

Iron Deficiency

Maintenance Treatment of Iron Deficiency in IBD Patients

1 Sites
245 Participants
COMPLETED
18 Years to 17 Years
NCT00292981 | PHASE 3 | INTERVENTIONAL

Hereditary Angioedema

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

14 Sites
57 Participants
COMPLETED
6 Years to 17 Years
NCT01108848 | PHASE 3 | OBSERVATIONAL

Includes: Hereditary Angioedema

Patient Registry Study of Berinert® in Normal Clinical Practice

40 Sites
318 Participants
COMPLETED
6 Years to 17 Years
NCT00848848 | PHASE 1 | INTERVENTIONAL

Influenza

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

1 Sites
450 Participants
COMPLETED
65 Years to 17 Years
NCT00958126 | PHASE 2 | INTERVENTIONAL

Influenza

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

11 Sites
1313 Participants
COMPLETED
18 Years to 17 Years
NCT05422326 | PHASE 2 | INTERVENTIONAL

Influenza, Human

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

18 Sites
260 Participants
COMPLETED
18 Years to 17 Years
NCT02053792 | PHASE 3 | INTERVENTIONAL

Hemophilia B

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

42 Sites
97 Participants
COMPLETED
12 Years to 70 Years
NCT01964989 | PHASE 3 | INTERVENTIONAL

Influenza Virus

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

167 Sites
10644 Participants
COMPLETED
6 Months to 71 Months
NCT01233440 | PHASE 1 | INTERVENTIONAL

Hemophilia B

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

20 Sites
25 Participants
COMPLETED
12 Years to 65 Years
NCT00520494 | PHASE 4 | INTERVENTIONAL

Common Variable Immunodeficiency

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

6 Sites
18 Participants
COMPLETED
1 Year to 70 Years
NCT04570267 | PHASE 1 | INTERVENTIONAL

Healthy

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

1 Sites
32 Participants
COMPLETED
20 Years to 55 Years
NCT05524467 | PHASE 1 | OBSERVATIONAL

Chronic Kidney Disease-associated Pruritus

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients

94 Sites
3100 Participants
COMPLETED
18 Years to 55 Years
NCT03972280 | PHASE 1 | INTERVENTIONAL

Hidradenitis Suppurativa

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

11 Sites
39 Participants
COMPLETED
18 Years to 75 Years
NCT02319460 | PHASE 1 | OBSERVATIONAL

Hemorrhage

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

1 Sites
2238 Participants
COMPLETED
18 Years to 75 Years
NCT04285827 | PHASE 1 | INTERVENTIONAL

Sickle Cell Disease

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

15 Sites
28 Participants
COMPLETED
18 Years to 60 Years
NCT01486927 | PHASE 2 | INTERVENTIONAL

Hemophilia A

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

56 Sites
175 Participants
COMPLETED
12 Years to 65 Years
NCT02552576 | PHASE 4 | INTERVENTIONAL

Von Willebrand Disease

Study of Voncento® in Subjects With Von Willebrand Disease

12 Sites
26 Participants
COMPLETED
12 Years to 65 Years
NCT01166074 | PHASE 4 | OBSERVATIONAL

Primary Immune Deficiency

Retrospective Chart Review of Subcutaneous IgG Use in Infants

5 Sites
27 Participants
COMPLETED
12 Years to 2 Years
NCT03442582 | PHASE 4 | OBSERVATIONAL

Influenza, Human

Afluria Pregnancy Registry

1 Sites
490 Participants
COMPLETED
12 Years to 2 Years
NCT01496274 | PHASE 2 | INTERVENTIONAL

Hemophilia B

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

30 Sites
63 Participants
COMPLETED
12 Years to 65 Years
NCT00168025 | PHASE 3 | INTERVENTIONAL

Agammaglobulinemia

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

0 Sites
89 Participants
COMPLETED
3 Years to 70 Years
NCT02015520 | PHASE 2 | INTERVENTIONAL

Rheumatoid Arthritis

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

55 Sites
143 Participants
COMPLETED
18 Years to 70 Years
NCT01361126 | PHASE 1 | INTERVENTIONAL

Hemophilia B

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

2 Sites
17 Participants
COMPLETED
12 Years to 65 Years
NCT03888066 | PHASE 3 | INTERVENTIONAL

Hyperkalemia

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

415 Sites
1195 Participants
COMPLETED
18 Years to 65 Years
NCT00810030 | PHASE 3 | INTERVENTIONAL

Inflammatory Bowel Disease

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

1 Sites
484 Participants
COMPLETED
18 Years to 65 Years
NCT00479648 | PHASE 2 | INTERVENTIONAL

Influenza

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

1 Sites
612 Participants
COMPLETED
18 Years to 65 Years
NCT00520780 | PHASE 3 | INTERVENTIONAL

Chronic Heart Failure

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

48 Sites
456 Participants
COMPLETED
18 Years to 65 Years
NCT01394562 | PHASE 3 | INTERVENTIONAL

Iron Deficiency

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure

1 Sites
174 Participants
COMPLETED
18 Years to 65 Years
NCT01113580 | PHASE 4 | INTERVENTIONAL

Influenza

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

1 Sites
120 Participants
COMPLETED
18 Years to 65 Years
NCT00496262 | PHASE 2 | INTERVENTIONAL

Fibrinogen Deficiency

Human Fibrinogen - Pharmacokinetics

15 Sites
15 Participants
COMPLETED
6 Years to 65 Years
NCT05962398 | PHASE 1 | OBSERVATIONAL

Hemophilia B

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

8 Sites
56 Participants
ENROLLING BY INVITATION
18 Years to 55 Years
NCT06617897 | PHASE 3 | INTERVENTIONAL

Acquired Fibrinogen Deficiency

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

0 Sites
90 Participants
NOT YET RECRUITING
18 Years to 65 Years
NCT05485961 | PHASE 2 | INTERVENTIONAL

Atherosclerotic Cardiovascular Disease

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

93 Sites
2310 Participants
RECRUITING
18 Years to 65 Years
NCT05568888 | PHASE 3 | INTERVENTIONAL

Traumatic Injury

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

113 Sites
8000 Participants
RECRUITING
15 Years to 50 Years
NCT06003387 | PHASE 3 | INTERVENTIONAL

Hemophilia B

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

3 Sites
35 Participants
RECRUITING
18 Years to 59 Years
NCT05937581 | PHASE 1 | INTERVENTIONAL

Complement Deficiencies

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

1 Sites
60 Participants
RECRUITING
18 Years to 64 Years
NCT04672733 | PHASE 3 | OBSERVATIONAL

Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

27 Sites
100 Participants
RECRUITING
18 Years to 11 Years
NCT06399289 | PHASE 3 | INTERVENTIONAL

Hemophilia B

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

6 Sites
23 Participants
RECRUITING
18 Years to 70 Years
NCT05766839 | PHASE 2 | INTERVENTIONAL

Hyperkalemia

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

6 Sites
36 Participants
RECRUITING
18 Years to 11 Years
NCT06524739 | PHASE 3 | INTERVENTIONAL

Post-COVID Postural Orthostatic Tachycardia Syndrome

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

27 Sites
177 Participants
RECRUITING
18 Years to 11 Years
NCT03805789 | PHASE 2 | INTERVENTIONAL

Acute-graft-versus-host Disease

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

34 Sites
310 Participants
RECRUITING
12 Years to 75 Years
NCT06008938 | PHASE 3 | OBSERVATIONAL

Hemophilia B

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

1 Sites
500 Participants
RECRUITING
18 Years to 65 Years
NCT05086575 | PHASE 3 | OBSERVATIONAL

Haemophilia B

Observatory of Patients With Haemophilia B Treated by IdElvion®

28 Sites
100 Participants
RECRUITING
6 Months to 59 Months
NCT05819775 | PHASE 3 | INTERVENTIONAL

Hereditary Angioedema (HAE)

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

13 Sites
20 Participants
RECRUITING
2 Years to 11 Years
NCT03684018 | PHASE 4 | INTERVENTIONAL

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Two Dose Levels of Privigen in Pediatric CIDP

8 Sites
30 Participants
RECRUITING
2 Years to 17 Years
NCT04091737 | PHASE 1 | INTERVENTIONAL

Anemia, Sickle Cell

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

1 Sites
1 Participants
TERMINATED
18 Years to 45 Years
NCT01100879 | PHASE 4 | INTERVENTIONAL

Iron-Deficiency Anemia

Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy

2 Sites
3 Participants
TERMINATED
18 Years to 64 Years
NCT00821717 | PHASE 3 | INTERVENTIONAL

Chronic Heart Failure

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

41 Sites
35 Participants
TERMINATED
18 Years to 11 Years
NCT03221842 | PHASE 3 | INTERVENTIONAL

Antibody-mediated Rejection

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

26 Sites
63 Participants
TERMINATED
18 Years to 17 Years
NCT04446000 | PHASE 1 | INTERVENTIONAL

Immune Complex-mediated Autoimmune Diseases

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

1 Sites
52 Participants
TERMINATED
18 Years to 55 Years
NCT01403064 | PHASE 2 | INTERVENTIONAL

Oral Mucositis

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

31 Sites
76 Participants
TERMINATED
18 Years to 65 Years
NCT03375606 | PHASE 1 | INTERVENTIONAL

Healthy

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

2 Sites
26 Participants
TERMINATED
20 Years to 55 Years
NCT03087058 | PHASE 2 | INTERVENTIONAL

Hyperkalemia

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

30 Sites
23 Participants
TERMINATED
2 Years to 17 Years
NCT02033317 | PHASE 2 | INTERVENTIONAL

Hyperkalemia

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

2 Sites
6 Participants
TERMINATED
18 Years to 70 Years
NCT04638634 | PHASE 1 | INTERVENTIONAL

Coronavirus Disease 2019 (COVID-19)

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

1 Sites
12 Participants
TERMINATED
18 Years to 65 Years
NCT02484638 | PHASE 2 | INTERVENTIONAL

Hemophilia A With Inhibitors

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

10 Sites
25 Participants
TERMINATED
12 Years to 65 Years
NCT00882414 | PHASE 2 | INTERVENTIONAL

Thrombocytosis

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

1 Sites
26 Participants
TERMINATED
18 Years to 60 Years
NCT03744910 | PHASE 3 | INTERVENTIONAL

Antibody-mediated Rejection

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

142 Sites
194 Participants
TERMINATED
18 Years to 75 Years
NCT01545050 | PHASE 2 | INTERVENTIONAL

Crohn's Disease

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

56 Sites
72 Participants
TERMINATED
18 Years to 64 Years
NCT01530256 | PHASE 1 | INTERVENTIONAL

Acute GvHD

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

5 Sites
3 Participants
TERMINATED
18 Years to 71 Years
NCT03779828 | PHASE 1 | OBSERVATIONAL

Chronic Inflammatory Demyelinating Polyneuropathy

Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP

10 Sites
11 Participants
TERMINATED
65 Years to 75 Years
NCT01445197 | PHASE 3 | INTERVENTIONAL

Hemophilia A

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

7 Sites
1 Participants
TERMINATED
28 Days to 11 Years
NCT00916656 | PHASE 3 | INTERVENTIONAL

Afibrinogenemia

Fibrinogen Concentrate (Human) - Efficacy and Safety Study

0 Sites
0 Participants
WITHDRAWN
18 Years to 71 Years
NCT04138485 | PHASE 2 | INTERVENTIONAL

Diffuse Cutaneous Systemic Sclerosis

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

77 Sites
0 Participants
WITHDRAWN
18 Years to 71 Years
NCT02258178 | PHASE 1 | OBSERVATIONAL

Pregnant Women, Influenza

Flucelvax Pregnancy Registry

1 Sites
0 Participants
WITHDRAWN
18 Years to 50 Years
NCT05625542 | PHASE 4 | OBSERVATIONAL

Chronic Kidney Disease-associated Pruritus

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients

0 Sites
0 Participants
WITHDRAWN
18 Years to 65 Years
NCT04938635 | PHASE 2 | INTERVENTIONAL

Beta-Thalassemia

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

7 Sites
0 Participants
WITHDRAWN
18 Years to 65 Years
NCT04519424 | PHASE 2 | INTERVENTIONAL

Coronavirus Disease 2019 (COVID-19)

CSL324 in COVID-19

0 Sites
0 Participants
WITHDRAWN
18 Years to 48 Months
NCT04281524 | PHASE 1 | INTERVENTIONAL

PICC-associated Thrombosis

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

0 Sites
0 Participants
WITHDRAWN
18 Years to 75 Years
NCT04806529 | PHASE 2 | INTERVENTIONAL

Influenza

An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older

0 Sites
0 Participants
WITHDRAWN
18 Years to 65 Years